Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 16, 2020

Swedish trial to assess prostate cancer drug for Covid-19

Swedish researchers have announced a new clinical trial to assess a prostate cancer drug, called Enzalutamide, for the treatment of Covid-19 patients.

Swedish researchers have announced a new clinical trial to assess a prostate cancer drug, called Enzalutamide, for the treatment of Covid-19 patients.

This nationwide trial is an alliance between Umeå University, Sahlgrenska Academy at the University of Gothenburg, Norrlands University Hospital in Umeå, and Sahlgrenska University Hospital in Gothenburg.

Researchers expect the drug to shorten the course of the disease and the requirement for intensive care.

Enzalutamide acts by inhibiting signals of testosterone, a male sex hormone, in turn affecting the TMPRSS2 enzyme, among others. TMPRSS2 is also required by SARS-CoV-2 to enter into cells and harm lungs.

Umeå University Wallenberg Centre for Molecular Medicine group leader Andreas Josefsson said: “Our objective is that this drug will reduce the amount of coronavirus that can reach lung cells by preventing the underlying process behind an enzyme.”

The trial, called Covidenza, will involve hospitalised individuals suffering from Covid-19, but not critically ill patients requiring intensive care. Participants will receive oral form of the drug over five days.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Commonly, the drug is given as a long-term treatment and this short treatment duration is expected to reduce the risks of potential side effects.

Participants will be continuously followed for six weeks and then after six months.

Apart from the collaborators, six Swedish medical regions intend to participate in the trial, while the hospitals in Malmö, Sundsvall and Jönköping are making preparations to begin the study.

Up to 600 patients are expected to be enrolled in the trial.

University of Gothenburg Sahlgrenska Academy researcher Karin Welén said: “We also have close collaborations internationally with not least the US where similar trials are commencing, and we are sharing experiences with each other.

“The spirit is high in collaborations both within research fields globally, as well as cross-disciplinarily to find drugs against Covid-19.”

The trial has secured Swedish Medical Products Agency approval.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU